Cargando…

Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison

CSL112 (apolipoprotein A‐I [apoA‐I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This phase I study aimed to compare the pharmacokinetics (PKs), pharmacodynamics (PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Bo, Goto, Shinya, Clementi, Regina, Feaster, John, Duffy, Danielle, Dalitz, Penelope, Airey, Jolanta, Korjian, Serge, Tortorici, Michael A., Roberts, John, Gibson, C. Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579388/ https://www.ncbi.nlm.nih.gov/pubmed/35933730 http://dx.doi.org/10.1111/cts.13361

Ejemplares similares

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
por: Kingwell, Bronwyn A., et al.
Publicado: (2022)

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
por: Gille, Andreas, et al.
Publicado: (2018)

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients
por: Zheng, Bo, et al.
Publicado: (2020)

Pharmacokinetics and Safety of CSL112 (Apolipoprotein A‐I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
por: Tortorici, Michael A., et al.
Publicado: (2018)

CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
por: Gille, Andreas, et al.
Publicado: (2018)

Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
por: Korjian, Serge, et al.
Publicado: (2023)

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
por: Michael Gibson, C., et al.
Publicado: (2016)

Correction to: Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity
por: Didichenko, Svetlana A., et al.
Publicado: (2016)

Caveolin-1-Mediated Apolipoprotein A-I Membrane Binding Sites Are Not Required for Cholesterol Efflux
por: Le Lay, Soazig, et al.
Publicado: (2011)

Structural properties of apolipoprotein A-I mimetic peptides that promote ABCA1-dependent cholesterol efflux
por: Islam, Rafique M., et al.
Publicado: (2018)

Conformational flexibility of apolipoprotein A-I amino- and carboxy-termini is necessary for lipid binding but not cholesterol efflux
por: Bedi, Shimpi, et al.
Publicado: (2022)

Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Lee, Jane J., et al.
Publicado: (2021)

Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells
por: Yano, Kouji, et al.
Publicado: (2016)

Mitochondrial function is involved in regulation of cholesterol efflux to apolipoprotein (apo)A-I from murine RAW 264.7 macrophages
por: Allen, Anne Marie, et al.
Publicado: (2012)

Guanosine effect on cholesterol efflux and apolipoprotein E expression in astrocytes
por: Ballerini, Patrizia, et al.
Publicado: (2006)

It’s Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
por: Marsche, Gunther
Publicado: (2015)

Apolipoprotein M promotes cholesterol uptake and efflux from mouse macrophages
por: Yao, Shuang, et al.
Publicado: (2021)

Fungal CSL transcription factors
por: Převorovský, Martin, et al.
Publicado: (2007)

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
por: Tricoci, Pierluigi, et al.
Publicado: (2015)

IMB2026791, a Xanthone, Stimulates Cholesterol Efflux by Increasing the Binding of Apolipoprotein A-I to ATP-Binding Cassette Transporter A1
por: Liu, Jikai, et al.
Publicado: (2012)

Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)
por: Pawaskar, Dipti, et al.
Publicado: (2021)

Chronic cerebral hypoperfusion induces ABCA1 and apolipoprotein A I mediated cellular cholesterol efflux by activating LXR/RXR in aging rat brain
por: Wang, Linhui, et al.
Publicado: (2012)

A short peptide of the C-terminal class Y helices of apolipoprotein A-I has preserved functions in cholesterol efflux and in vivo metabolic control
por: Edmunds, Shelley J., et al.
Publicado: (2020)

Importance of Apolipoprotein A-I in Multiple Sclerosis
por: Gardner, Lidia A., et al.
Publicado: (2015)

Apolipoprotein A-I and Cancer
por: Zamanian-Daryoush, Maryam, et al.
Publicado: (2015)

On the Aggregation of Apolipoprotein A-I
por: Frankel, Rebecca, et al.
Publicado: (2022)

The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the β-Amyloid Efflux Across the Blood-Brain Barrier in vitro
por: Dal Magro, Roberta, et al.
Publicado: (2019)

Dishevelled limits Notch signalling through inhibition of CSL
por: Collu, Giovanna M., et al.
Publicado: (2012)

Cholesterol efflux capacity assay using immobilized liposomes and apolipoprotein B-depleted serum
por: Sapa, Hima Rani
Publicado: (2019)

ALICE HMPID Csl photocathode coating station
Publicado: (2003)

Dissipative Continuous Spontaneous Localization (CSL) model
por: Smirne, Andrea, et al.
Publicado: (2015)

Apolipoprotein A-I modulates HDL particle size in the absence of apolipoprotein A-II
por: Melchior, John T., et al.
Publicado: (2021)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Fission Yeast CSL Proteins Function as Transcription Factors
por: Oravcová, Martina, et al.
Publicado: (2013)

Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes
por: Christensen, Pernille M., et al.
Publicado: (2017)

Interactions of Apolipoprotein A-I with High-Density Lipoprotein Particles
por: Nguyen, David, et al.
Publicado: (2013)

β(3)-Adrenoceptor activation upregulates apolipoprotein A-I expression in HepG2 cells, which might further promote cholesterol efflux from macrophage foam cells
por: Gao, Xia-qing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_924e718iksutae585096r5kjtn